Highlights Newsletter 4
This newsletter presents you the following key sessions:
5. Treatment breaks acceptable in standard first-line therapy of advanced renal cell carcinoma
This newsletter presents you the following key sessions:
5. Treatment breaks acceptable in standard first-line therapy of advanced renal cell carcinoma
Medical writer
Medical writer